| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 22.54 mm | 22.54 mm | 22.54 mm | 22.54 mm | 22.54 mm | 22.54 mm |
| Cash burn (monthly) | 2.60 mm | (no burn) | 4.17 mm | 3.41 mm | 4.29 mm | 3.16 mm |
| Cash used (since last report) | 6.00 mm | n/a | 9.62 mm | 7.85 mm | 9.89 mm | 7.29 mm |
| Cash remaining | 16.54 mm | n/a | 12.92 mm | 14.69 mm | 12.65 mm | 15.25 mm |
| Runway (months of cash) | 6.4 | n/a | 3.1 | 4.3 | 2.9 | 4.8 |
| 13F holders | Current |
|---|---|
| Total holders | 84 |
| Opened positions | 13 |
| Closed positions | 7 |
| Increased positions | 24 |
| Reduced positions | 21 |
| 13F shares | Current |
|---|---|
| Total value | 41.78 bn |
| Total shares | 57.50 mm |
| Total puts | 200.00 |
| Total calls | 2.40 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | 7.53 mm | $7.01 bn |
| EcoR1 Capital Fund | 6.08 mm | $24.45 mm |
| Rubric Capital Management | 5.32 mm | $4.96 bn |
| BlackRock | 3.93 mm | $3.67 bn |
| Biotechnology Value Fund L P | 3.85 mm | $4.43 mm |
| BVF | 3.85 mm | $3.60 bn |
| Madison Avenue Partners | 3.72 mm | $3.48 bn |
| Vanguard | 3.15 mm | $2.94 bn |
| Siren, L.L.C. | 2.85 mm | $2.66 bn |
| Acadian Asset Management | 1.85 mm | $1.73 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Mar 25 | Papadopoulos Stelios | Stock Option Common Stock | Grant | Acquire A | No | No | 0.49 | 90,000 | 44.10 k | 90,000 |
| 26 Feb 25 | Margaret A. Alexander | Common Stock | Sell | Dispose S | No | No | 0.56 | 5,279 | 2.96 k | 73,406 |
| 26 Feb 25 | Jeffrey A Rona | Common Stock | Sell | Dispose S | No | No | 0.56 | 3,902 | 2.19 k | 67,973 |
| 20 Feb 25 | Jeremy M Levin | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.57 | 1,650,000 | 940.50 k | 1,650,000 |
